With our AI-enabled drug discovery platform and the dedication of our brilliant, hard-working team, we have discovered differentiated therapies for some of the most challenging and pervasive diseases — at record pace.
We’re immensely proud of how far we’ve come since our founding in 2019. And we’re just getting started.
Mechanism: Novel (Non-Kinase)
Indication: Atopic Dermatitis
ENV-294 is a first-in-class, oral small molecule, with JAK-inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 is completing Phase 1b trials and has initiated Phase 2a trials in atopic dermatitis.
Mechanism: Novel (Non-Kinase)
Indication: Asthma
Demonstrating its pipeline-in-a-product potential, ENV-294 has initiated Phase 2a trials in asthma following IND clearance.
Mechanism: Novel (Hormone Mimetic)
Indication: Obesity
ENV-308 is a first-in-class, oral small molecule for the treatment of obesity. In addition to compelling efficacy, ENV-308 shows highly encouraging safety and tolerability for long-term use. ENV-308 is currently in Phase 1 trials.
Mechanism: TL1A+ Pathway Inhibitor
Indication: Inflammatory Bowel Disease
ENV-6946 is a first-in-class, gut-preferred, oral small molecule that offers a "multi-biologic in a pill" potential via a novel single target for the treatment of inflammatory bowel disease. ENV-6946 is currently in Phase 1 trials.
Mechanism: TL1A+ Pathway Inhibitor
Indication: Multiple Inflammatory, Fibrotic
ENV-096 is a first-in-class, oral single-target, multi-cytokine inhibitor being studied in multiple liver conditions. ENV-096 is currently in IND-enabling studies and is expected to be in Phase 1 trials in 2026.
Mechanism: Novel
Indication: Multiple Mental Health Disorders
ESN-M is a first-in-class, oral small molecule being studied in multiple mental health disorders. ESN-M is currently in IND-enabling studies.
Mechanism: Novel
Indication: Idiopathic Pulmonary Fibrosis
ESN-A is a first-in-class, oral small molecule demonstrating potent efficacy in multiple preclinical models of fibrosis. ESN-A is currently in IND-enabling studies.
Mechanism: MRGPRX4 Antagonist
Indication: Cholestatic Pruritus
ESN-C is a potential best-in-class oral MRGPRX4 antagonist to treat the debilitating itch associated with cholestatic conditions. ESN-C has completed IND-enabling studies.
Mechanism: TGFβ Inhibitor
Indication: Lung Fibrosis
ESN-Y2 is a potential best-in-class, inhaled TGFβ inhibitor being studied in multiple lung fibrotic conditions. ESN-Y2 is currently in IND-enabling studies.
Mechanism: TGFβ Inhibitor
Indication: Fibrostenotic Crohn's
ESN-Y is a potential best-in-class, gut-preferred, oral TGFβ inhibitor being studied in fibrostenotic Crohn's disease. ESN-Y has reached DC and is ready for IND-enabling studies.
Mechanism: TGFβ Inhibitor
Indication: Derm Fibrosis
ESN-Y1 is a potential best-in-class, locally injected TGFβ inhibitor being studied in multiple derm fibrotic conditions. ESN-Y1 has reached DC and is ready for IND-enabling studies.
Mechanism: MRGPRX2 Antagonist
Indication: Multiple Inflammatory
ESN-G is a potential best-in-class, oral small molecule being studied in multiple inflammatory diseases. ESN-G has reached DC and is ready for IND-enabling studies.
Mechanism: NRF2 Agonist
Indication: Undisclosed
ESN-N is a potential best-in-class, topical NRF2 agonist being studied in various neurosensory conditions. ESN-N has reached DC and is ready for IND-enabling studies.
Mechanism: TL1A+ Pathway Inhibitor
Indication: Multiple Neuroinflammatory
ESN-X2 is a first-in-class, brain-penetrant oral small molecule that offers "multi-biologic in a pill" potential via a novel single target for the treatment of multiple neuroinflammatory conditions. ESN-X2 has reached DC and is ready for IND-enabling studies.
Mechanism: TL1A Antagonist
Indication: Multiple Inflammatory
ESN-T is a potential best-in-class, oral small molecule inhibitor of TL1A for the treatment of inflammatory bowel disease. Multiple promising scaffolds are in optimization with a DC expected in 2026.
Mechanism: IL-4/13 Antagonist
Indication: Multiple Inflammatory
ESN-F is a potential best-in-class, oral small molecule inhibitor of IL-4/13 for the treatment of multiple inflammatory diseases. Multiple promising scaffolds are in optimization with a DC expected in 2026.
ENV-294 is a first-in-class, oral small molecule, with JAK-inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 is completing Phase 1b trials and has initiated Phase 2a trials in atopic dermatitis.
Demonstrating its pipeline-in-a-product potential, ENV-294 has initiated Phase 2a trials in asthma following IND clearance.
ENV-308 is a first-in-class, oral small molecule for the treatment of obesity. In addition to compelling efficacy, ENV-308 shows highly encouraging safety and tolerability for long-term use. ENV-308 is currently in Phase 1 trials.
ENV-6946 is a first-in-class, gut-preferred, oral small molecule that offers a "multi-biologic in a pill" potential via a novel single target for the treatment of inflammatory bowel disease. ENV-6946 is currently in Phase 1 trials.
ENV-096 is a first-in-class, oral single-target, multi-cytokine inhibitor being studied in multiple liver conditions. ENV-096 is currently in IND-enabling studies and is expected to be in Phase 1 trials in 2026.
ESN-M is a first-in-class, oral small molecule being studied in multiple mental health disorders. ESN-M is currently in IND-enabling studies.
ESN-A is a first-in-class, oral small molecule demonstrating potent efficacy in multiple preclinical models of fibrosis. ESN-A is currently in IND-enabling studies.
ESN-C is a potential best-in-class oral MRGPRX4 antagonist to treat the debilitating itch associated with cholestatic conditions. ESN-C has completed IND-enabling studies.
ESN-Y2 is a potential best-in-class, inhaled TGFβ inhibitor being studied in multiple lung fibrotic conditions. ESN-Y2 is currently in IND-enabling studies.
ESN-Y is a potential best-in-class, gut-preferred, oral TGFβ inhibitor being studied in fibrostenotic Crohn's disease. ESN-Y has reached DC and is ready for IND-enabling studies.
ESN-Y1 is a potential best-in-class, locally injected TGFβ inhibitor being studied in multiple derm fibrotic conditions. ESN-Y1 has reached DC and is ready for IND-enabling studies.
ESN-G is a potential best-in-class, oral small molecule being studied in multiple inflammatory diseases. ESN-G has reached DC and is ready for IND-enabling studies.
ESN-N is a potential best-in-class, topical NRF2 agonist being studied in various neurosensory conditions. ESN-N has reached DC and is ready for IND-enabling studies.
ESN-X2 is a first-in-class, brain-penetrant oral small molecule that offers "multi-biologic in a pill" potential via a novel single target for the treatment of multiple neuroinflammatory conditions. ESN-X2 has reached DC and is ready for IND-enabling studies.
ESN-T is a potential best-in-class, oral small molecule inhibitor of TL1A for the treatment of inflammatory bowel disease. Multiple promising scaffolds are in optimization with a DC expected in 2026.
Development Candidate Declared
THE PROBLEM
Over 10% (30M+) of the US population suffers from atopic dermatitis, commonly known as eczema. Yet, today’s treatments for moderate-to-severe eczema either rely on injectables that pose a significant barrier to patient care or oral therapies that come with potentially serious toxicities. Moreover, despite these treatments, half of all eczema to atopic dermatitis patients respond poorly to therapy.
THE MOLECULE
We are developing a first-in-class medicine that fights inflammation in a new way. This novel mechanism allows it to exert potentially powerful anti-inflammatory effects without the same toxicities that have burdened previous treatments – and can be delivered orally via a pill.
THE PROGRESS
Our molecule has demonstrated robust efficacy comparable to Jak-inhibitors in preclinical atopic dermatitis models but without their concomitant risks as evidenced by pre-clinical safety testing. It is currently in Phase 1b clinical trials.
THE PROBLEM
Inflammatory bowel disease, or IBD, which includes both Crohn’s disease and Ulcerative Colitis, is a chronic autoimmune disorder that damages the digestive tract and disrupts the lives of more than 3 million people in the United States. IBD has limited treatment options that have proven to cause long-term remission in patients.
Moreover, many safe existing treatments have to be delivered as injections or pills that come with significant safety liabilities.
THE MOLECULE
We are developing a new therapeutic approach to treating IBD. Our first-in-class molecule hits multiple clinically validated pathways simultaneously, has been engineered to be preferentially present in the gut, and can be administered as a convenient pill. With ESN-6946, we have the potential to deliver improved safety, efficacy, and convenience.
THE PROGRESS
This powerful molecule is currently in Phase 1 trials.
THE PROBLEM
Obesity affects over 40% of adults in the United States and nearly 900 million adults globally. It is a primary driver of diabetes, cardiovascular disease, fatty liver disease, and reduced quality of life. While modern injectable therapies can induce substantial weight loss, they are difficult to sustain long-term due to tolerability, cost, access, and high discontinuation rates. Upon discontinuation, the majority of patients rapidly regain weight and lose metabolic benefits, leaving no effective solution for durable maintenance.
THE MOLECULE
We are developing a first-in-class small-molecule medicine designed to support long-term metabolic balance. ENV-308 mimics an endogenous anti-obesity hormone, engaging central satiety and reward pathways while restoring metabolic sensitivity in obesity. This differentiated mechanism enables appetite regulation and metabolic control without relying on incretin signaling — and is designed for once-daily oral dosing suitable for chronic use.
THE PROGRESS
ENV-308 has demonstrated sustained appetite suppression, steady body-weight loss, and complete prevention of weight regain following GLP-1 withdrawal in preclinical obesity models at any target weight, with weight loss driven predominantly by fat mass preservation. The molecule has shown a favorable safety and tolerability profile in IND-enabling studies and is advancing through Phase 1 trials in healthy and obese individuals.
Together, we can rapidly multiply humanity’s knowledge of the natural
world’s chemistry and solve many of the greatest challenges in human
and planetary health. We’d love your support.